Can the Q-TWiST method provide information on patients' preferences without collecting preference data from the patients? In reply

被引：0
|
作者：
Zee, B [1 ]
James, K [1 ]
Pater, J [1 ]
机构：
[1] NCI, Clin Trials Grp, Kingston, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 1998年 / 16卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3718 / 3718
页数：1
相关论文
共 44 条
  • [1] Can the Q-TWiST method provide information on patients' preferences without collecting preference data from the patients?
    Messori, A
    Trippoli, S
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (11) : 3716 - 3717
  • [2] Analyzing Oncology Clinical Trial Data Using the Q-TWiST Method: Clinical Importance and Sources for Health State Preference Data*
    Dennis A. Revicki
    David Feeny
    Timothy L. Hunt
    Bernard F. Cole
    [J]. Quality of Life Research, 2006, 15 : 411 - 423
  • [3] Analyzing oncology clinical trial data using the Q-TWiST method: Clinical importance and sources for health state preference data
    Revicki, DA
    Feeny, D
    Hunt, TL
    Cole, BF
    [J]. QUALITY OF LIFE RESEARCH, 2006, 15 (03) : 411 - 423
  • [4] Quality-adjusted time without symptoms and toxicity (Q-twist) of fotemustine compared with dacarbazine in patients with disseminated malignant melanoma
    Simons, W. R.
    Aamdal, S.
    Hauschild, A.
    Mohr, P.
    Grob, J. J.
    [J]. VALUE IN HEALTH, 2007, 10 (06) : A322 - A322
  • [5] Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma
    Lee, Chung-Han
    Wan, Yin
    Smith, Alan
    Xie, Ran
    Motzer, Robert J.
    [J]. EUROPEAN UROLOGY OPEN SCIENCE, 2021, 31 : 1 - 9
  • [6] Quality-adjusted time without symptoms or toxicity (Q-TWiST) for lenvatinib plus everolimus versus everolimus monotherapy in patients with advanced renal cell carcinoma
    Lee, C. H.
    Wan, Y.
    Smith, A.
    Xie, R.
    Motzer, R. J.
    [J]. ONKOUROLOGIYA, 2021, 17 (04): : 54 - 64
  • [7] Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer (mCRC) treated with fruquintinib in a phase II clinical trial.
    Li, Jin
    Xu, Ruihua
    Bai, Yuxian
    Xu, Jianming
    Liu, Tianshu
    Shen, Lin
    Wang, Liwei
    Pan, Hongming
    Han, Rubing
    Chen, Yun
    Peng, Cike
    Fan, Songhua
    Hua, Ye
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [8] Quality-adjusted time without symptoms or toxicity (Q-TWiST) of lenvatinib plus everolimus versus everolimus monotherapy in patients with advanced renal cell carcinoma (RCC).
    Lee, Chung-Han
    Wan, Yin
    Smith, Alan D.
    Xie, Ran
    Motzer, Robert J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer (mCRC) treated with fruquintinib in the randomized phase III FRESCO trial.
    Bai, Yu-Xian
    Qin, Shukui
    Li, Jin
    Deng, Yanhong
    Yang, Lei
    Xu, Rui-hua
    Zhong, Haijun
    Chen, Zhendong
    Pan, Hongming
    Guo, Weijian
    Shu, Yongqian
    Peng, Cike
    Chen, Yun
    Li, Hongyan
    Wang, Ning
    Guo, Xiaojun
    Wang, Wei
    Fan, Songhua
    Xu, Jian-Ming
    Shen, Lin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial
    Marino, P.
    Sfumato, P.
    Joly, F.
    Fizazi, K.
    Oudard, S.
    Culine, S.
    Habibian, M.
    Boher, J-M.
    Gravis, G.
    [J]. EUROPEAN JOURNAL OF CANCER, 2017, 84 : 27 - 33
12345